Related Experiment Video
Updated: Sep 27, 2026

Infecting Mice with Malassezia spp. to Study the Fungus-Host Interaction
Published on: November 6, 2019
Catheter-related Malassezia furfur fungemia in immunocompromised patients
G R Barber1, A E Brown, T E Kiehn
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Purpose, Patients, And Methods:
Malassezia furfur has usually been described as a cause of catheter-related sepsis in neonates receiving intravenous lipid emulsion. We report seven cases of catheter-related M. furfur fungemia that occurred in seven immunocompromised patients including four adults and three children who were not neonates. Only two of these patients were receiving concurrent intravenous lipid emulsion.
Results:
All positive blood cultures were obtained from a central venous access device, one of which was a port device. Quantitative M. furfur colony counts ranged from 50 cfu/mL to greater than 1,000 cfu/mL. All seven patients were treated with amphotericin B. Blood drawn through the central lines of three patients yielded additional organisms. One central venous access device required removal due to persistently positive M. furfur blood cultures despite treatment with amphotericin B.
Conclusion:
We conclude that catheter-related M. furfur fungemia occurs in immunocompromised patients with central venous access devices whether or not they are receiving intravenous lipids. Prompt, aggressive treatment with amphotericin B (1 mg/kg/d) may spare patients removal of their central venous access device. Further studies are needed to determine the role of endogenous lipids in the development of catheter-related M. furfur fungemia and to determine if there is a seasonal incidence in populations other than neonates, since all of our cases occurred between late March and July.
Insights
Catheter-related Malassezia furfur fungemia can occur in immunocompromised patients, not just neonates. Early amphotericin B treatment may prevent central venous access device removal.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Critical Care Medicine
Background:
- Malassezia furfur is a known cause of catheter-related sepsis in neonates, often linked to lipid emulsions.
- Previous understanding primarily associated M. furfur fungemia with neonatal populations and intravenous lipid use.
Purpose of the Study:
- To report cases of catheter-related Malassezia furfur fungemia in non-neonatal immunocompromised patients.
- To investigate the association between M. furfur fungemia and central venous access devices in this patient group.
- To evaluate treatment outcomes and the role of lipid emulsions.
Main Methods:
- Retrospective case series of seven immunocompromised patients (four adults, three children) with M. furfur fungemia.
- Analysis of blood cultures from central venous access devices.
- Review of patient demographics, lipid emulsion use, and treatment regimens.
Main Results:
- All seven patients had positive blood cultures from central venous access devices.
- Only two patients received concurrent intravenous lipid emulsion.
- Quantitative M. furfur colony counts varied, and amphotericin B was the primary treatment.
- One device required removal due to persistent fungemia despite treatment.
Conclusions:
- Catheter-related M. furfur fungemia is a risk in immunocompromised patients with central venous access devices, independent of lipid emulsion use.
- Prompt amphotericin B treatment (1 mg/kg/d) can potentially avoid device removal.
- Further research is needed on the role of endogenous lipids and potential seasonal incidence in non-neonatal populations.
Related Concept Videos
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Fungal Group Zygomycota
Fungal Phylum Microsporidia
The Skin Microbiota
Cryptococcal Meningitis
Candidiasis

